熱門資訊> 正文

Alkermes的alixorexton获得FDA孤儿药地位，用于治疗特发性嗜睡症

2026-06-12 01:34

阿爾凱默斯(ALKS) 0
高盛(GS) 0

The US FDA has granted orphan drug designation to Alkermes' (ALKS) alixorexton for idiopathic hypersomnia.
The oral orexin 2 receptor agonist is currently in phase 2.
The condition is characterized by difficulty waking up and extreme sleepiness during the day.

More on Alkermes

Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alkermes plc 2026 Q1 - Results - Earnings Call Presentation
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company
Alkermes posts late-stage trial win for Lumryz in new sleep disorder
Alkermes Q1 2026 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。